<DOC>
	<DOC>NCT01204762</DOC>
	<brief_summary>At least 1 dose of pegIFNÎ» will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda (Lambda) when administered in combination with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic hepatitis B(CHB) infection employing a sequential therapy approach</brief_summary>
	<brief_title>Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen</brief_title>
	<detailed_description>Part B sub study is Open Label</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Infection with the hepatitis B virus (HBV) and positive for the hepatitis B e antigen Between the ages of 18 and 70 Have not been previously treated with an interferon HBV nucleos(t)idenaive Not infected with the hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) Do not have a serious liver, psychiatric, blood, thyroid, lung, heart or eye disease Able to tolerate oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>